RN Mobile Menu

Search form


Rheumatology Network

Focus on Axial Spondyloarthritis

In this series of stories we focus on highlighting common axSpA manifestations, compare treatment recommendations and summarize the newly condensed ASAS-EULAR treatment recommendations. (©Illustrart/Shutterstock.com)



Recent Content


In this slideshow, we offer a glance at newly approved treatments for rheumatoid arthritis, juvenile arthritis, osteoporosis and fingernail psoriasis, among other conditions.


Chronic back pain, arthritis and enthesitis are among common axSpA manifestations, but no two patients are alike. Here, we highlight key presentations.


EULAR-ASAS have updated the 2010 guidelines for axSpA emphasizing treat to target, tapering and for the first time, cost considerations.

Back Pain (©Lightspring/Shutterstock.com)

In this slideshow, we highlight the 13 ASAS-EULAR treatment management guidelines for axial spondyloarthritis.


Early stage RA treated with tocilizumab or tocilizumab and methotrexate realized clinical benefits with no safety concerns at two years.


Research shows that for women with autoimmune disease, the increase risk of infection during pregnancy is associated with steroids, not DMARDs.


Estimates for juvenile idiopathic arthritis differ widely depending on which set of criteria doctors use.

By clicking Accept, you agree to become a member of the UBM Medica Community.